Boehringer Ingelheim Pharmaceuticals on Wednesday announced that its Spiriva Respimat (tiotropium bromide) inhalation spray is now available by prescription through pharmacies across the United States.
Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration approved Spiriva Respimat (tiotropium bromide) inhalation spray as a treatment for bronchospasm associated with chronic obstructive pulmonary disease.
The big news in incontinence is Oxytrol, which doesn't reach store shelves until September. It's a switched product coming from Merck Consumer Care that brings an entirely new indication to the over-the-counter space — overactive bladder in women.
Merck on Friday announced the Food and Drug Administration has approved the switch of Oxytrol for Women (oxybutynin transdermal system, 3.9 mg/day) from prescription-only to nonprescription, creating a new category — overactive bladder in women — in the OTC area.
According to a Food and Drug Administration post Friday, the FDA's Nonprescription Drugs Advisory Committee will be meeting Nov. 9 regarding the partial switch application from prescription to over the counter of Oxytrol (oxybutynin transdermal system), as submitted by MSD Consumer.